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Several studies have demonstrated the effectiveness of mAbs specific for tumor
cell surface molecules astherapeutic agents to inhibit tumor growth both experimen-
tally (1-4) and in clinical trials (5-7). Since B cell lymphomas bear unique deter-
minants (idiotopes) on their surface Ig molecules, and since only a small number
ofnormal B cells share that same idiotype, antiidiotype mAb could be used as an
antitumor agent without affecting a significant fraction ofthe normal Bcell popula-
tion (8, 9). There are, however, two problems with this approach: (a) the high rate
ofsomatic mutation in Iggenes (10, 11), which can alter theepitope tobe recognized
by mAb; and (b) the necessity to establish a different antiidiotypic mAb for each
individual B cell lymphoma.
For T cell tumors, the situation appears to be different. Recent analysis ofTCR
V gene segments has revealed verylimited, ifany, somatic mutation amongthe TCR
genes isolated from various T cell clones, hybridomas, and T cell tumor lines (12).
Furthermore, the numberofdifferentTCR V gene segments isrelatively smallboth
in man and mouse (13), and the evidence indicates that deletion of several V gene
segments in certain strains ofmice doesnot affect the general immune status ofsuch
mouse strains (14). These observations raise the intriguing possibility that mAbs
directed to determinant ofTCR Vframework regions, rather than to unique idio-
topesofthe TCR, might be useful fortreatingTcell tumors without compromising
host immunity. Moreover, because ofthe small number ofTCR V genes, it seems
feasible to produce a panel ofmAbs specific foreach ofthese V gene products. These
mAbs maybe effective in diagnosis or clinical protocols dealing with spontaneously
arising T cell tumors expressing one of the V gene products.
Herewe explorethe feasibilityofthis approach in mice andshowthatmAbsspecific
for V06 TCR products given four times over a 2-wk period prevent the growth of
a V06+ syngeneic T cell tumor without compromising the immune status ofthese
mice to other experimental antigens. To our knowledge, this is the first demonstra-
tion ofthe effectiveness ofpreventing tumor growth with a mAb having specificity
for a particular subset of T cells expressing a defined V(3 TCR marker.
Materials and Methods
Mice.
￿
C57BL/6and B10.BR mice(purchased from TheJacksonLaboratories, BarHarbor,
ME) of both sexes, 6-10 wk old, were used.
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Cell Lines and mAbs .
￿
Two thymoma cell lines, C6VL and EL-4, derived from C57BL/6,
and oneAKRderived thymoma, BW5147, were maintained in culture in 10% FCSDME .
mAb directed to determinant on theTCR V08 chain (KJ16-133, rat IgG2a) (15) and on the
Vf6 chain (RR4-7, rat IgG2b) (16) were partially purified from ascites fluids .
Immunofluorescent Staining
￿
Two-step surface immunofluorescence staining was performed
as described previously (16) . Briefly, tumor cells or nylon wool nonadherent spleen cells were
incubated with saturating doses ofmAb (100 pl) for 30 min at 4°C, washed, and further in-
cubated with FITC-conjugated goat anti-rat Ig (Caltag Laboratories, San Francisco, CA)
for another 30 min at 4°C . Stained samples were analyzed on a FACScan flow cytometer
(Becton Dickinson Immunocytometory Systems, Mountain View, CA) .
T Cell Proliferation Assays .
￿
Proliferative responses ofT cells to antigen and mitogen (Con
A) were measured by procedures described previously (17) . Briefly, mice were immunized
with keyhole limpet hemocyanin (KLH, 100 Fig/mouse) in CFA at the base of the tail . 7 d
later, 10 5 cells, recovered from inguinal lymph nodes, were stimulated with KLH (10,ug/ml),
Con A (2 1~g/ml), or medium alone in flat-bottomed microtiter plates in a final volume of
200 pl of 5% FCS DME . The proliferative response was measured on day 3 following a
6-h pulse with [ 3H]thymidine .
Generation ofAlloantigen-speck CTL.
￿
CytolyticT cell responses were measured by culturing
5 x 106C57BL/6 spleen cells and an equal number of irradiated (2,000 rad) B10.BR spleen
cells in 24-well tissue culture plates in a final volume of 2 ml 5o7o FCS DME . 5 d later, cells
were recovered and tested for cytolytic activity using 5ICr-labeled BW5147 (H-2') target
cells in standard Cr-release assays. Lytic units (LU) were calculated from plots of titrated
cytolytic activities . 1 LU is defined as the number of effector cells required to lyse 50 17o of
10 4 target cells under the specific conditions of this assay system .
Results
Treatment ofTCell TumorIn Vioo.
￿
To test the possible therapeutic efficacy ofmAbs
specific for V136 on T cell tumor growth in vivo, a large panel ofT cell tumors de-
rived from C57BL/6 mice were screened for the expression ofV#6 or VQ8 TCR
using a mAb specific for V06 (RR4-7) and another specific for V08 (KJ-16.133) .
FIGURE 1 .
￿
Surface expression ofTCR
by C57BL/6 splenicT cells andC6VL
tumor cells . Nylon wool-purified sple-
nicT cells andC6VL tumor cells were
analyzed by indirect immunofluores-
cence flow cytometey for cell surface
expression of TCR using KJ 16-133
(antiV13 8 .1 and 8 .1 antibody; kindly
provided byDr.J . Kapplerand P Mar-
rack, NationalJewish Center for Im-
munology and Respiratory Medicine,
Denver, CO) and RR4-7 (antiV06 an-
tibody) . Control staining was deter-
mined with the fluoresceinated goat
anti-rat Ig alone .KANAGAWA ET AL.
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TABLE I
Treatment of C57BL/6 Mice Bearing C6VL Tumor Cells
with Anti-14,66 mAb
Groups of5 C57BL/6 mice were injected with either C6VL or EL-4 tumor cells
intravenously (2 x 104/mouse in a final volume of 500 ul). Mice were treated
with either RR4-7 (anti-1406, 150,ug/mouse), KJ16 (anti-VS8, 150 Fig/mouse),
or none. Treatment was initiated 24 h after the tumor inoculation and given
every 3 d for 12 d.
These two antibodies stain 8 and 13%, respectively, ofnylon wool nonadherent B6
spleen cells. Onetumor, C6VL, wasidentified with antiVS6mAb stainingandusage
of this TCR gene was confirmed in mRNA analyses using a V06 probe.
The results ofthe first two efficacy tests ofantiV06 mAb on the growth ofa Va6+
tumor are shown in Table I. Panels ofC57BL/6 mice were injected intravenously
with lethal numbers (20 x 104) C6VL (V06+) or EL4 (V06-) tumor cells and then
treated with anti14(36 mAb, anti14/38 mAb, or nothing(150 jig/injection, i.p., four
times in 12 d). All mice given EL4 tumor cells died, regardless ofwhich antibody
they received in subsequent treatment. By comparison, however, of mice injected
with VQ6+ tumorcells, only 3/10 animals died after treatment with anti14/36 mAb,
while all died (15/15) if treated with antiV08 mAb or nothing. Furthermore, use
ofisotype-matched control IgG2b antibodydid not protectmicefromtumor-related
death. It should be noted that of the three mice that died with 14/36+ tumor cells
and antiV06 treatment, these had significantly prolonged survival times (>60 d)
compared with the other treatment groups (-30 d).
C6VL tumor cells were recovered from a liver mass in a mouse that developed
atumordespite treatmentwith anti14(36mAb. Thesecellswere analyzedforsurface
expression ofV06 TCR by flow cytometric analysis using RR4-7 (antiV06). The
data shown in Fig. 2 revealed that this tumor retained the original V06 TCR on
a majority ofits cells, indicating that treatment ofthis 1406+ tumor with antiV06
mAbdoes not result in theselectionofsignificant number ofTCR negative variants
in vivo.
Effect ofAnti-V,B6mAbon Host Immune Responses.
￿
Flowcytometric analysisofnylon
wool nonadherent spleen cells from mice treated with antiV06 mAb, using anti-
V06 and anti14(38 mAbs, indicated that the number of 1406+ T cells was greatly
reduced while number of14/38+ T cells was normal in both treated and nontreated
Exp.
T cell
tumor Treatment Death Mean survival
d t SD
A I C6VL Anti-VO6 2/5 >60
II C6VL Anti-14/38 5/5 30 t 3
III C6VL None 5/5 30 t 2
IV EL-4 Anti-1406 5/5 51 t 4
V EL-4 None 5/5 53 t 5
B I C6VL Anti-V#6 1/5 >60
11 C6VL None 5/5 29 +_ 2
III EL-4 Anti-V,66 5/5 30 t 2
IV EL-4 None 5/5 30 t 31516
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FLUORESCENCE INTENSITY
(LOG)
FIGURE 2.
￿
V06 TCR expression
on C6VL tumor cells recovered
from mice treated with RR4-7 an-
tibody. Tumor cells from liver in a
mouse that developed a tumor de-
spite treatment with RR4-7 Ab
were cultured in vitro for 3 d. Cells
were stained with medium alone
(A) or RR4-7Ab (B) followed by
fluoresceinated goat anti-rat Ig.
Stained samples were analyzed by
FACScan flow cytometry.
groups (Table II). These data demonstrate that antiV06 mAb can eliminate Va6+
tumor cells as well as normal T cells that are V06+, which comprise -8% of the
peripheral T cell pool.
Despite elimination of T cells bearing V06 TCR, this treatment seemed not to
have significant effect on the immune status ofthese mice. T cell responses ofmAb
treated animals, measured by proliferative response to KLH and Con A, and the
generationofallospecific CTL, werecomparableto those ofnontreated animals (Table
II).
Immunity to the Tumor Cells after n Ab Treatment.
￿
Mice that had been successfully
treatedwith RR4-7 antibodyto prevent C6VL tumor growth were rechallenged with
the same tumor cells without further antibody treatment (Table III). All ofthese
mice showed complete resistance to further tumor challenge.
Discussion
In this article we use an experimental murine model to show that a rat mAb of
the IgG2b isotype specific foran epitope determined by the TCR V06 gene is effec-
tive in preventing growth invivoofa syngeneic Tcell tumor expressing aV06TCR.
This antibody appears to be effectiveininhibiting tumor growth without any significant
TABLE II
Effect of In Vivo Anti-V,66 Antibody on the Host Immune Response
TCR
￿
CTL
expression
￿
In vitro proliferative response'
￿
response
Mice
￿
V08
￿
V06
￿
KLH
￿
Con A
￿
None
￿
in vitro
0 70
￿
cpm x 10-3 ￿L0 1
Control
￿
14.81
￿
7.5
￿
65 t 8 .5
￿
385 t 12
￿
3 .4 ± 0.5
￿
20
Treated
￿
16.5
￿
1 .1
￿
73 t 22
￿
384 t 54 3.5 t 0.5
￿
17
C57BL/6 mice received an intraperitoneal injection of 150,ug ofRR4-7 anti-
body in PBS. 3 d after injection, spleen cells were analyzed for the expression
of V06 TCR and tested for the generation of the CTL response against H-2k
alloantigens, as described in Materials and Methods.
3 d after antibody treatment, mice were tested for the antigen-specific prolifer-
ative responses as described in Materials and Methods .
$ Percent T cells stained; mean of three individual determinations.
§ Mean of triplicate cultures ; t SD.
II LU/106 recovered cells.KANAGAWA ET AL.
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TABLE III
Acquisition of Immunity to the C6VL Tumor Cell in Mice Surviving
after Antibody Treatment
Mice
￿
Death
￿
Mean survival
d t SD
Naive
￿
5/5
￿
32 +_ 3
Survivors
￿
0/4
￿
>65
Mice that survived in the initial tumorchallenge from the group I shown in Ta-
ble I and naive age-matched control mice received intravenous injection of C6VL
tumor cells (2 x 104/mouse). The time between the final RR4-7 antibody in-
jection and the C6VL tumor rechallenge was >60 d .
compromise to the immune status of the treated host despite the fact that it also
eliminates normal T cells of the V06+ subset that comprise nearly 10°Io of the pe-
ripheral T lymphocyte pool.
Two lines of evidence support the conclusion that the effectiveness of antiV06
in inhibiting tumorgrowth is dependent on expression of atarget molecule on tumor
cells that is some epitope of the V06 gene product of the TCR. Mice treated with
mAb specific for a different V(3 epitope, V08, do not show inhibition of V06 tumor
growth, and mice treated with antiV06 show no growth inhibition of EL4, a different
syngeneic T cell tumor.
How treatment with antiVO antibodies inhibits growth ofV(3+ tumor cells in vivo
is not clear, but two general possibilities can be considered. First, like MHC/an-
tigen, mAbs specific for T cell receptors cause activation and lymphokine produc-
tion of T cell hybridomas, and subsequent inhibition of growth both in vivo and
in vitro (18, 19). However, we could find no evidence ofthe capacity ofC6VL tumor
cells to respond in any way to stimulation with RR4-7 in vitro. Thus we consider
it unlikely that elimination of V06+ tumor cells with antiV06 antibody requires
their activation in vivo. Secondary, antiV(3 antibodies might participate in some
cellular mechanisminvolvingbinding to Fc receptors ofeffector cells to cause inhibi-
tion of tumor growth . In favor of this possibility is the fact that antibodies of the
rat IgG2b subclass have been found to be the most effective in eliminating target
cells in vivo (20). In addition, in not yet complete studies, we have found that anti-
V06 together with murine spleen cells bearing Fc receptor inhibit the growth of C6VL
in vitro, and that treatment of mice in vivo with F(ab')2 fragment of antiV06 mAb
is not as effective as treatment with the whole molecule.
The findings that anti-V06-treated mice that survived initial tumorchallenge are
resistant to further challenge without additional treatment with antibody is particu-
larly striking. In these experiments, the number of normal peripheral V06+ T cells
had returned to normal, thus it seems unlikely that residual levels of antiV06 anti-
body from the first treatment can account for subsequent tumor resistance. Active
immunization of mice with irradiated syngeneic tumor cells also causes resistance
to subsequent challenge. Thus, our provisional interpretation of the effect of these
antibodies is that they retard tumor growth by some cell-mediated, Fc-dependent
mechanism to a degree sufficient to permit the opportunity for host immune an-
titumor responses that would otherwisebe overwhelmedby rapid tumorcell growth.1518
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The findings that antitumor treatment with antiV(3 antibody does not compromise
the immune response capacity to other test antigens despite the fact that a significant
portion of the peripheral T cell pool is also eliminated do not rule out the possibility
that lack of T cells bearing one particular V gene segment may cause a deficit in
the response to certain antigens. However, these findings are comparable to the prior
studies, in that nearly one-third of Va chains are genetically deleted in certain strains
of mice, causing a significant deficit in the expressed repertoire of TCR without
jeopardizing their immune response potential.
While the mechanisms ofantiV(3 antibody protectionagainst T cell tumor growth
clearly need to be investigated further, the important point to emphasize here is that
an epitope expressed on a TCR V gene product of normal cells can be used as a
target molecule for mAb therapy of a T cell neoplasm. Since the number of genes
encoding known TCR V/3 segment is only 21 in mouse and 35 in man (13), it seems
a reasonable approach to establish panels of mAb specific for each V/3 gene segment
for use both diagnostically and therapeutically in the treatment of T cell tumor ex-
pressing clonally distributed TCR (21).
Summary
To test whether antibodies directed to TCR affect T cell tumor growth in vivo,
mice were inoculated intravenously with C6VL tumor cells expressing V06 TCR
and then treated intraperitoneally with mAb specific for Va6 TCR. Administration
ofantiV06 antibody prolonged survival ofmice bearing V06-expressing tumor cells
and it led to the induction of host immunity to the tumor cells in surviving animals .
This treatment eliminated not only tumor cells bearing Va6 TCR but also normal
host T cells expressing V06 T cell receptors. However, the lack of V06-expressing
T cells in such treated mice did not result in generalized immune disfunction. These
data demonstrate the utility of antiTCR V segment antibody in the treatment of
T cell tumors. Most importantly, since the number of V genes for the T cell antigen
receptor is limited, both in man and in mouse, it should be possible to establish
a panel of mAbs directed to each V gene product and use such antibodies in the
treatment of T cell neoplasms.
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